STEM CELL THERAPEUTI | TalkMarkets | Page 1
No data available
No data available

People who follow this stock (32)

View All

Latest Posts

About This Stock More About This Stock
Calithera Biosciences: An Under The Radar Opportunity
Article By: Scott Matusow
Monday, December 7, 2020 5:30 AM EDT
Calithera is a high-risk, high reward speculative investment addressing high unmet and under-served needs markets, with a lower bar data threshold to meet. Calithera has an important near-term catalyst shortly upcoming.
In this article: PFE, TRIL, EXEL, CALA Also: BMY, MRK, ESALF, GILD
Read
Bloom Burton's David Martin Zeroes In On Under-The-Radar Biotech
Article By: The Life Sciences Report
Thursday, February 12, 2015 5:59 PM EDT
Biotechnology indices have been on a rapid ascent for three years, and 2015 appears to be off to the races as well.
In this article: NBI, BMY, MRK, RHHBY, ENDP, TRIL
Read
Being Early On An Early Asset: Trillium May Be A Diamond In The Rough Immunotherapy Stock
Article By: Jake King
Wednesday, October 29, 2014 9:59 AM EDT
Trillium Therapeutics is an immuno-oncology company developing novel cancer therapeutics. Their primary target, the CD47 antigen, is generating significant attention from industry and academia alike.
In this article: TRIL, CELG
Read
All Posts

Latest Tweets for $TRIL

No tweets yet!

PARTNER HEADLINES